lifonebart   Click here for help

GtoPdb Ligand ID: 14696

Synonyms: VHB-937 | VHB937
Compound class: Antibody
Comment: Lifonebart (VHB937) is a fully human anti-TREM2 monoclonal antibody, with agonist activity at TREM2 on microglia [2]. It was designed for potential to treat inflammation-associated neurodegenerative conditions.
Peptide sequences for the heavy and light chains of lifonebart match sequences that are claimed in patent US11492402B2, specifically for antibody clones with the code name MOR044698 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Lifonebart (VHB937) was progresed as a clinical candidate for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease, MND, and Lou Gehrig's disease) and Alzheimer's disease. Following lack of significant efficacy in the Phase II ASTRALS ALS study, development for this indication was terminated in September 2026.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06643481 A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) Phase 2 Interventional Novartis The ASTRALS study. Development in ALS was terminated in 2026.
NCT07094516 A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease Phase 2 Interventional Novartis